Rewind Therapeutics

Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuvens Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by l...